. "Zahradov\u00E1, Lenka" . "V roce 2004 prob\u011Bhla v na\u0161em centru prvn\u00ED klinick\u00E1 studie f\u00E1ze II, kde byl pacient\u016Fm s mnoho\u010Detn\u00FDm myelomem (MM) pod\u00E1v\u00E1n monoklon\u00E1ln\u00ED imunoglobulin (Id-protein) po konjugaci s imunogenn\u00EDm nosi\u010Dem keyhole limpet hemocyanin (KLH). Vakc\u00EDna byla pou\u017Eita ve skupin\u011B 12 nemocn\u00FDch se stabiln\u00EDm nebo m\u00EDrn\u011B aktivn\u00EDm onemocn\u011Bn\u00EDm. V\u00FDsledky nazna\u010Dily, \u017Ee imunitn\u00ED syst\u00E9m nemocn\u00FDch je schopen reakce na podan\u00FD antigen, kter\u00FD v\u0161ak nen\u00ED natolik imunogenn\u00ED, aby vyvolal klinickou odpov\u011B\u010F. Proto byla v na\u0161ich laborato\u0159\u00EDch p\u0159ipravena vakc\u00EDna nov\u00E9 generace s vyu\u017Eit\u00EDm dendritick\u00FDch bun\u011Bk (DB), kter\u00E9 jsou pova\u017Eov\u00E1ny za nej\u00FA\u010Dinn\u011Bj\u0161\u00ED antigen-prezentuj\u00EDc\u00ED bu\u0148ky. DB byly z\u00EDsk\u00E1ny z perifern\u00ED krve pacient\u016F s MM a kultivov\u00E1ny 9 dn\u016F za p\u0159\u00EDtomnosti cytokin\u016F IL-4 a GM-CSF. P\u00E1t\u00FD den kultivace byl p\u0159id\u00E1n autologn\u00ED Id-protein vyizolovan\u00FD z plazmy pacient\u016F metodou afinitn\u00ED chromatografie. \u00DApln\u00E9 dozr\u00E1n\u00ED DB bylo dokon\u010Deno p\u0159id\u00E1n\u00EDm TNF-alfa." . . "[500EA04B4191]" . "14110" . "Multiple myeloma; Dendritic cell; vaccine."@en . . "RIV/00216224:14110/07:00019218!RIV10-MZ0-14110___" . . "Mich\u00E1lek, Jaroslav" . . . "Vyu\u017Eit\u00ED dendritick\u00FDch bun\u011Bk loadovan\u00FDch monoklon\u00E1ln\u00EDm imunoglobulinem k vakcinaci pacient\u016F s mnoho\u010Detn\u00FDm myelomem: preklinick\u00E9 v\u00FDsledky klinick\u00E9 studie f\u00E1ze II." . . . . "5"^^ . "RIV/00216224:14110/07:00019218" . "O\u010Dadl\u00EDkov\u00E1, Darina" . "5"^^ . . . "The use of dendritic cells loaded with monoclonal immunoglobulin for the vaccination af myeloma patients: the preclinical results of a phase I/II clinical trial."@en . "V roce 2004 prob\u011Bhla v na\u0161em centru prvn\u00ED klinick\u00E1 studie f\u00E1ze II, kde byl pacient\u016Fm s mnoho\u010Detn\u00FDm myelomem (MM) pod\u00E1v\u00E1n monoklon\u00E1ln\u00ED imunoglobulin (Id-protein) po konjugaci s imunogenn\u00EDm nosi\u010Dem keyhole limpet hemocyanin (KLH). Vakc\u00EDna byla pou\u017Eita ve skupin\u011B 12 nemocn\u00FDch se stabiln\u00EDm nebo m\u00EDrn\u011B aktivn\u00EDm onemocn\u011Bn\u00EDm. V\u00FDsledky nazna\u010Dily, \u017Ee imunitn\u00ED syst\u00E9m nemocn\u00FDch je schopen reakce na podan\u00FD antigen, kter\u00FD v\u0161ak nen\u00ED natolik imunogenn\u00ED, aby vyvolal klinickou odpov\u011B\u010F. Proto byla v na\u0161ich laborato\u0159\u00EDch p\u0159ipravena vakc\u00EDna nov\u00E9 generace s vyu\u017Eit\u00EDm dendritick\u00FDch bun\u011Bk (DB), kter\u00E9 jsou pova\u017Eov\u00E1ny za nej\u00FA\u010Dinn\u011Bj\u0161\u00ED antigen-prezentuj\u00EDc\u00ED bu\u0148ky. DB byly z\u00EDsk\u00E1ny z perifern\u00ED krve pacient\u016F s MM a kultivov\u00E1ny 9 dn\u016F za p\u0159\u00EDtomnosti cytokin\u016F IL-4 a GM-CSF. P\u00E1t\u00FD den kultivace byl p\u0159id\u00E1n autologn\u00ED Id-protein vyizolovan\u00FD z plazmy pacient\u016F metodou afinitn\u00ED chromatografie. \u00DApln\u00E9 dozr\u00E1n\u00ED DB bylo dokon\u010Deno p\u0159id\u00E1n\u00EDm TNF-alfa."@cs . "H\u00E1jek, Roman" . "460017" . . . . "Vyu\u017Eit\u00ED dendritick\u00FDch bun\u011Bk loadovan\u00FDch monoklon\u00E1ln\u00EDm imunoglobulinem k vakcinaci pacient\u016F s mnoho\u010Detn\u00FDm myelomem: preklinick\u00E9 v\u00FDsledky klinick\u00E9 studie f\u00E1ze II."@cs . . . "Vyu\u017Eit\u00ED dendritick\u00FDch bun\u011Bk loadovan\u00FDch monoklon\u00E1ln\u00EDm imunoglobulinem k vakcinaci pacient\u016F s mnoho\u010Detn\u00FDm myelomem: preklinick\u00E9 v\u00FDsledky klinick\u00E9 studie f\u00E1ze II."@cs . "Vyu\u017Eit\u00ED dendritick\u00FDch bun\u011Bk loadovan\u00FDch monoklon\u00E1ln\u00EDm imunoglobulinem k vakcinaci pacient\u016F s mnoho\u010Detn\u00FDm myelomem: preklinick\u00E9 v\u00FDsledky klinick\u00E9 studie f\u00E1ze II." . . . "Kov\u00E1\u0159ov\u00E1, Lucie" . "Background: Adjuvant immunotherapy with antigen-loaded dendritic cells (DCs) represents a novel and relatively non-toxic treatment modality for multiple myeloma (MM). Malignant cells in MM produce a monoclonal immunoglobulin (idiotypic protein) which is considered a tumor-specific antigen and can be used for the induction of T lymphocytes. To enhance the anti-myeloma immune response, the idiotypic protein (Id-protein) can be loaded into autologous DCs and used for vaccination. Aims: The aim of this study was to evaluate DC-based vaccine preclinically and test the safety and the immune response of the vaccine in patients with MM. Patients and Methods: Pre-clinical testing was performed in 8 patients with MM. DC loaded with autologous myeloma cells were used for autologous T cell stimulation in vitro. After succesful preclinical testing, we have vaccinated 4 patients with stable disease or asymptomatic slow progressive disease according to EBMT criteria."@en . "The use of dendritic cells loaded with monoclonal immunoglobulin for the vaccination af myeloma patients: the preclinical results of a phase I/II clinical trial."@en . "P(NR8945)" . .